Behrens, Frank http://orcid.org/0000-0001-8750-7186
Leage, Soyi Liu http://orcid.org/0000-0002-2812-3980
Sapin, Christophe http://orcid.org/0000-0001-7655-7129
Baou, Celine El http://orcid.org/0000-0002-7212-1835
De La Torre, Inmaculada
Meszaros, Gabriella
Schett, Georg http://orcid.org/0000-0001-8740-9615
Combe, Bernard http://orcid.org/0000-0003-4002-1861
van den Bosch, Filip http://orcid.org/0000-0002-3561-5932
Gossec, Laure http://orcid.org/0000-0002-4528-310X
Funding for this research was provided by:
Eli Lilly and Company
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 28 May 2021
Revised: 16 August 2021
Accepted: 20 August 2021
First Online: 13 September 2021
Change Date: 19 February 2022
Change Type: Update
Change Details: The Funding information has been updated.
Change Date: 4 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10067-021-05966-3
Declarations
:
: SPIRIT-H2H was conducted in accordance with the ethical principles of the Declaration of Helsinki; all patients provided written informed consent and the study protocol was approved by the ethical review board (17/LO/0794) prior to the start of study-related procedures.
: Not applicable.
: Not applicable.
: Frank Behrens has received research grants from Celgene, Chugai, Janssen, Pfizer, and Roche and consultation/speaker fees from AbbVie; Boehringer Ingelheim; Celgene; Chugai; Eli Lilly and Company; Genzyme; Gilead Sciences, Inc.; Janssen; Merck; Novartis; Pfizer; Roche; Sanofi; and UCB. Soyi Liu Leage and Celine El Baou are employees of Eli Lilly and Company. Christophe Sapin, Inmaculada De La Torre, and Gabriella Meszaros are shareholders and employees of Eli Lilly and Company. Georg Schett has served on speakers bureaus for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Roche, and UCB. Bernard Combe has received grant/research support from Novartis, Pfizer, and Roche-Chugai; served as a consultant for AbbVie; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen; Pfizer; Roche-Chugai; and Sanofi; and served on speakers bureaus for Bristol Myers Squibb; Eli Lilly and Company; Gilead Sciences, Inc.; Merck Sharp & Dohme; Pfizer; and Roche-Chugai. Filip van den Bosch has received grant/research support from AbbVie, Merck, and UCB; served as a consultant for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Sanofi, and UCB Pharma; and served on speakers bureaus for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galapagos, Janssen, Merck, Novartis, Pfizer, Sanofi, and UCB Pharma. Laure Gossec has received grant/research support from Amgen, Eli Lilly and Company, Galapagos, Janssen, Pfizer, Sandoz, and Sanofi and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Biogen, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB.